title: The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder.
abstract: BACKGROUND
  To investigate the effect of prostaglandin depletion by means of COX-inhibition on cholinergic enhanced spontaneous contractions.
  
  
  METHODS
  The urethra and bladder of 9 male guinea pigs (weight 270-300 g) were removed and placed in an organ bath with Krebs' solution. A catheter was passed through the urethra through which the intravesical pressure was measured. The muscarinic agonist arecaidine, the non-selective COX inhibitor indomethacin, and PGE2 were subsequently added to the organ bath. The initial average frequency and amplitude of spontaneous contractions in the first 2 minutes after arecaidine application were labelled F(ini) and P(ini), respectively. The steady state frequency (F(steady)) and amplitude (P(steady)) were defined as the average frequency and amplitude during the 5 minutes before the next wash out.
  
  
  RESULTS
  Application of 1 μM PGE2 increased the amplitude of spontaneous contractions without affecting frequency. 10 μM of indomethacin reduced amplitude but not frequency.The addition of indomethacin did not alter F(ini) after the first application (p = 0.7665). However, after the second wash, F(ini) was decreased (p = 0.0005). F(steady), P(steady) and P(ini) were not significantly different in any of the conditions. These effects of indomethacin were reversible by PGE2 addition..
  
  
  CONCLUSIONS
  Blocking PG synthesis decreased the cholinergically stimulated autonomous contractions in the isolated bladder. This suggests that PG could modify normal cholinergically evoked response. A combination of drugs inhibiting muscarinic receptors and PG function or production can then become an interesting focus of research on a treatment for overactive bladder syndrome.
authors: Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. sajjad_r@yahoo.com
authors: Mohammad S
authors: MS
authors: Rahnama'i
authors: Gommert A
authors: GA
authors: van Koeveringe
authors: Philip E V
authors: PE
authors: van Kerrebroeck
authors: Stefan G G
authors: SG
authors: de Wachter
mesh_terms: D000818:Animals; D001115:Arecoline / Q000031:analogs & derivatives* / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015232:Dinoprostone / Q000494:pharmacology; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology*; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D001743:Urinary Bladder / Q000187:drug effects*
chemical_list: D016861:Cyclooxygenase Inhibitors; D018721:Muscarinic Agonists; C015688:arecaidine; D001115:Arecoline; D015232:Dinoprostone; D007213:Indomethacin
references: Nat Rev Urol. 2012 Mar 13;9(5):283-90
references: 22410675
references: Exp Physiol. 2003 May;88(3):343-57
references: 12719759
references: J Urol. 1995 Jun;153(6):2034-8
references: 7752389
references: BJU Int. 2010 Feb;105(4):540-8
references: 19673869
references: J Urol. 2011 Jan;185(1):315-22
references: 21075388
references: Neurourol Urodyn. 2011 Apr;30(4):619-25
references: 21254196
references: Neurourol Urodyn. 2008;27(6):466-74
references: 18092336
references: Scand J Urol Nephrol Suppl. 2004;(215):48-53
references: 15545196
references: Eur J Pharmacol. 2000 Feb 4;388(3):267-73
references: 10675736
references: Br J Pharmacol. 1980 Aug;69(4):573-7
references: 6254593
references: BJU Int. 2005 Jan;95(1):149-56
references: 15638914
references: Physiol Rev. 1999 Oct;79(4):1193-226
references: 10508233
references: Eur J Pharmacol. 1988 Jan 12;145(2):105-12
references: 3162418
references: J Urol. 2006 May;175(5):1773-6; discussion 1776
references: 16600756
references: J Cell Mol Med. 2009 Sep;13(9B):3069-81
references: 18752640
references: Eur Urol. 2003 Jan;43(1):1-5
references: 12507537
references: BJU Int. 2007 Oct;100(4):919-29
references: 17822470
references: Annu Rev Pharmacol Toxicol. 1998;38:97-120
references: 9597150
references: Arch Int Pharmacodyn Ther. 1982 Sep;259(1):31-9
references: 6129833
references: Eur Urol. 2010 Jan;57(1):171-2
references: 20178729
references: Am J Physiol Renal Physiol. 2008 Aug;295(2):F507-14
references: 18508878
references: J Cell Mol Med. 2009 Sep;13(9B):3236-50
references: 19243470
references: BJU Int. 2005 Sep;96 Suppl 1:37-42
references: 16083453
references: BJU Int. 2005 May;95(7):1002-5
references: 15839921
references: Urology. 2004 Dec;64(6 Suppl 1):7-11
references: 15621221
references: J Pharmacol Sci. 2008 Feb;106(2):193-8
references: 18285653
references: Int J Urol. 2005 Oct;12(10):875-80
references: 16323980
references: BJU Int. 2007 Sep;100(3):668-78
references: 17627783
references: Can Urol Assoc J. 2011 Oct;5(5 Suppl 2):S131-3
references: 21989523
references: J Smooth Muscle Res. 2007 Dec;43(6):219-27
references: 18285663
references: Naunyn Schmiedebergs Arch Pharmacol. 1986 Dec;334(4):463-7
references: 2434871
references: BJU Int. 2006 Sep;98(3):503-7
references: 16925744
references: Pharmacol Res. 1992 Jan;25(1):13-20
references: 1738753
references: Urology. 2002 May;59(5 Suppl 1):43-50
references: 12007522
references: J Urol. 2011 Jan;185(1):341-6
references: 21075387
references: J Urol. 2010 Mar;183(3):1241-7
references: 20096878
references: Br J Pharmacol. 2009 Jun;157(4):607-19
references: 19371347
references: Urology. 2004 Mar;63(3 Suppl 1):24-31
references: 15013649
references: BJU Int. 2007 Aug;100(2):419-29
references: 17617145
references: Ann N Y Acad Sci. 1971 Apr 30;180:363-85
references: 4106477